Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma

BACKGROUND: Metabolic toxicities of mTOR inhibitors (mTORi) are well characterized. The purpose of the study was to investigate the relationship between these metabolic toxicities and mTORi efficacy. METHODS: From 2007 to 2011, metabolic toxicities were retrospectively collected in patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Jebali, M., Elaidi, R., Brizard, M., Fouque, J., Takouchop, C., Sabatier, B., Oudard, S., Medioni, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217652/
https://www.ncbi.nlm.nih.gov/pubmed/28061764
http://dx.doi.org/10.1186/s12885-016-2993-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217652/
https://www.ncbi.nlm.nih.gov/pubmed/28061764
http://dx.doi.org/10.1186/s12885-016-2993-7

Ejemplares similares